Amgen Says Imdelltra Combo Reduced Risk Of Death By 58% In First-Line Lung Cancer

By Reuters News

Oct 24 (Reuters) - Amgen Inc AMGN.O:

  • AMGEN: NEARLY 80% OF PATIENTS ON IMDELLTRA-IMFINZI ALIVE AT ONE YEAR VERSUS 53% WITH DURVALUMAB ALONE & PROGRESSION-FREE SURVIVAL MORE THAN TRIPLED

  • AMGEN: GRADE 3 OR HIGHER ADVERSE EVENTS OCCURRED IN 20.9% WITH IMDELLTRA PLUS IMFINZI VERSUS 10.8% WITH IMFINZI ALONE

  • AMGEN: IMDELLTRA IN COMBINATION WITH IMFINZI REDUCED RISK OF DEATH BY 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER

  • AMGEN: SAFETY PROFILE OF IMDELLTRA IN COMBINATION WITH DURVALUMAB CONSISTENT WITH KNOWN SAFETY PROFILES OF INDIVIDUAL MEDICINES

  • AMGEN: IMDELLTRA PLUS DURVALUMAB EXTENDS MEDIAN OVERALL SURVIVAL TO 21.1 MONTHS VERSUS 12.7 MONTHS WITH DURVALUMAB ALONE

Source text: https://tinyurl.com/ye2yvf5k

Further company coverage: AMGN.O

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.